Roche Holding AG (RHHBY)
- Previous Close
29.75 - Open
29.71 - Bid --
- Ask --
- Day's Range
29.36 - 29.73 - 52 Week Range
29.36 - 40.48 - Volume
2,231,295 - Avg. Volume
2,745,977 - Market Cap (intraday)
191.468B - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
15.01 - EPS (TTM)
1.96 - Earnings Date Jul 25, 2024
- Forward Dividend & Yield 1.35 (4.54%)
- Ex-Dividend Date Mar 14, 2024
- 1y Target Est
37.86
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
www.roche.com103,605
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: RHHBY
Performance Overview: RHHBY
Trailing total returns as of 5/2/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RHHBY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RHHBY
Valuation Measures
Market Cap
193.58B
Enterprise Value
215.63B
Trailing P/E
15.15
Forward P/E
12.17
PEG Ratio (5yr expected)
1.20
Price/Sales (ttm)
2.88
Price/Book (mrq)
5.90
Enterprise Value/Revenue
3.57
Enterprise Value/EBITDA
11.63
Financial Highlights
Profitability and Income Statement
Profit Margin
19.02%
Return on Assets (ttm)
12.44%
Return on Equity (ttm)
37.86%
Revenue (ttm)
60.44B
Net Income Avi to Common (ttm)
11.5B
Diluted EPS (ttm)
1.96
Balance Sheet and Cash Flow
Total Cash (mrq)
10.51B
Total Debt/Equity (mrq)
92.75%
Levered Free Cash Flow (ttm)
8.6B
Research Analysis: RHHBY
Company Insights: RHHBY
RHHBY does not have Company Insights